Welcome Video
Goals
- To learn about the latest and future directions in novel therapeutics for primary cardiac sarcomas
- To learn about how a patient traverses the health care system once diagnosed with a cardiac tumour
Objectives
- Develop an understanding of an approach to primary sarcomas from a molecular approach
- Describe the importance of MDM2 and CDk4 in the assessment and treatment of Primary cardiac tumours
- Differentiate the roles of MDM2 and checkpoint inhibitors in malignant primary cardiac tumours
- Compare the journey of a patient with a cardiac tumour in different countries
- Provide a platform for discussion for future clinical trials in cardiac sarcoma
Stay up-to-date on twitter
Program Director
Dr. Robert James Cusimano
BSc MSc MD FRCSC FACS
Division of Cardiovascular Surgery
Peter Munk Cardiac Centre
Professor, Department of Surgery, University of Toronto
The David and Stacey Cynamon Professorship in Cardiovascular Innovation and Education Department of Surgery, University of Toronto
Program Co-Chairs
Robin Jones BSC MB BS MRCP MD(Res)
Professor
Head of Sarcoma Unit, Royal Marsden Hospital, London
Vinod Ravi MD
Professor
Department of Sarcoma Medical Oncology
Department of Genomic Medicine
Clinical Director, Translational Research Accelerator Program
U.T.M.D. Anderson Cancer Center, Austin, Texas, United States
Albiruni Razak MB BCh BM BCh
Associate Professor, Division of Oncology and Hematology
Faculty of Medicine, University of Toronto
Staff Medical Oncologist, Solid Tumor Program (Sarcoma & Phase 1 Drug Development), Princess Margaret Cancer Centre and Mount Sinai Hospital
Medical Oncology Lead, Sarcoma Program, Princess Margaret Cancer Centre and Mount Sinai Hospital, Toronto
Conference Planning Committee
Dr. Steven Lawrence Cusimano, BSc MD CCFP
Family Health Organization (FHO)
Hamilton Family Health Team (HFHT)
Parkdale Medical Centre
Conference Flyer
